Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02948543Phase 3Unknown

Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

Role: collaborator

NCT03091764Completed

Evaluation of a Patient-Reported Symptom Index for NMIBC

Role: collaborator

NCT00096408Phase 3Completed

Laparoscopic Approach to Cancer of the Endometrium

Role: collaborator

NCT00604994Completed

Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer

Role: collaborator

All 4 trials loaded